CNR1 and neoplasm: In contrast, the treatment with AM281, the selective antagonist of CB1, showed, in tumor cells, opposite effects at 0.5 and 1 μM, suggesting that the biological effects of CB1 impairment could be dependent on the concentration and cell type, as already reported in the literature.